Director at Quest Diagnostics (NYSE: DGX) receives 1,142 RSUs
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Diaz Luis reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Luis Diaz received an equity grant in the form of restricted stock units. On May 20, 2026, he was awarded 1,142 shares of Quest Diagnostics common stock at no purchase price, increasing his directly held stake to 5,196 shares. This represents routine stock-based compensation rather than an open-market trade.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Diaz Luis
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 1,142 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 5,196 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
RSU grant size: 1,142 shares
Transaction date: May 20, 2026
Grant price per share: $0.00 per share
+1 more
4 metrics
RSU grant size
1,142 shares
Restricted stock units of common stock granted to Luis Diaz
Transaction date
May 20, 2026
Date of RSU award to director Luis Diaz
Grant price per share
$0.00 per share
Compensation grant, not an open-market purchase
Shares held after grant
5,196 shares
Luis Diaz direct ownership of Quest Diagnostics common stock
Key Terms
restricted stock units, Grant, award, or other acquisition, Common Stock
3 terms
restricted stock units financial
"Represents an award of restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What insider transaction did DGX director Luis Diaz report?
Director Luis Diaz reported an award of 1,142 restricted stock units of Quest Diagnostics common stock. The grant was recorded at no purchase price, reflecting stock-based compensation rather than an open-market transaction, and increased his directly owned position to a total of 5,196 shares.
When did Luis Diaz receive restricted stock units from Quest Diagnostics (DGX)?
Luis Diaz received the award of restricted stock units on May 20, 2026. The Form 4 shows this as a grant of 1,142 Quest Diagnostics common shares, recorded with a per-share transaction price of zero, indicating compensation instead of a market purchase.
Was the Luis Diaz DGX Form 4 a stock purchase or compensation grant?
The Luis Diaz Form 4 reports a compensation grant, not a market purchase. It records 1,142 restricted stock units of Quest Diagnostics common stock with a transaction code "A," meaning a grant, award, or other acquisition at a price of zero per share.
What does the footnote on the DGX Form 4 for Luis Diaz explain?
The footnote explains that the reported transaction represents an award of restricted stock units. This clarifies that Luis Diaz’s 1,142-share increase in Quest Diagnostics common stock resulted from stock-based compensation rather than an open-market buy or derivative option exercise.
Does the Luis Diaz Quest Diagnostics Form 4 involve any derivative securities?
The filing shows no derivative securities for this transaction. It reports only a non-derivative award of 1,142 restricted stock units of Quest Diagnostics common stock, and the derivative holdings section is empty, indicating no options or similar instruments disclosed in this Form 4.